key: cord-0816233-0ypzpumc
authors: Fukuma, Nobuaki; Hulke, Michelle L.; Brener, Michael I.; Golob, Stephanie; Zilinyi, Robert; Zhou, Zhipeng; Tzimas, Christos; Russo, Ilaria; McGroder, Claire; Pfeiffer, Ryan; Chong, Alexander; Zhang, Geping; Burkhoff, Daniel; Leon, Martin B.; Maurer, Mathew; Moses, Jeffrey W.; Uhlemann, Anne-Catrin; Hibshoosh, Hanina; Uriel, Nir; Szabolcs, Matthias J.; Redfors, Björn; Marboe, Charles C.; Baldwin, Matthew R.; Tucker, Nathan R.; Tsai, Emily J.
title: Molecular Pathophysiology of Cardiac Injury and Cardiac Microthrombi in Fatal COVID-19: Insights from Clinico-histopathologic and Single Nuclei RNA Sequencing Analyses
date: 2021-07-27
journal: bioRxiv
DOI: 10.1101/2021.07.27.453843
sha: 46cebce978cc868f2f28c8d47fc958b898b9d835
doc_id: 816233
cord_uid: 0ypzpumc

Cardiac injury is associated with critical COVID-19, yet its etiology remains debated. To elucidate the pathogenic mechanisms of COVID-19-associated cardiac injury, we conducted a single-center prospective cohort study of 69 COVID-19 decedents. Of six cardiac histopathologic features, microthrombi was the most commonly detected (n=48, 70%). We tested associations of cardiac microthrombi with biomarkers of inflammation, cardiac injury, and fibrinolysis and with in-hospital antiplatelet therapy, therapeutic anticoagulation, and corticosteroid treatment, while adjusting for multiple clinical factors, including COVID-19 therapies. Higher peak ESR and CRP during hospitalization were independently associated with higher odds of microthrombi. Using single nuclei RNA-sequence analysis, we discovered an enrichment of pro-thrombotic/anti-fibrinolytic, extracellular matrix remodeling, and immune-potentiating signaling amongst cardiac fibroblasts in microthrombi-positive COVID-19 hearts relative to microthrombi-negative COVID-19. Non-COVID-19 non-failing hearts were used as reference controls. Our cumulative findings identify the specific transcriptomic changes in cardiac fibroblasts as salient features of COVID-19-associated cardiac microthrombi.

In severe COVID-19, cardiac manifestations like arrhythmias, 1 myocardial infarction, 2,3 1 acute heart failure, 4-6 and cardiogenic shock 7 are prevalent and associated with increased 2 mortality. 8, 9 Both direct and indirect mechanisms of COVID-19-associated cardiac injury have 3 been postulated, 10 yet details remain elusive. Early theories that COVID-19 cardiac injury 4 reflected acute viral myocarditis have since been disproven by the rarity of cases that meet 5 histologic criteria for myocarditis. Additionally, diverse cardiac histopathologic findings, 6 including endothelial cell damage and inflammatory cell infiltrates without associated cardiac 7 necrosis, 2,11,12 have been described on autopsy of COVID-19 decedents but at variable 8 prevalence. Subsequently, the detection of microvascular thrombi in the hearts, 13,14 lungs, [15] [16] [17] [18] [19] 9 liver, 20 brain, 21 and skin 22 of COVID-19 patients have raised the possibility that, in severe cases, 10 COVID-19 may be more akin to a systemic illness. Such reports of multi-organ microthrombi, 11 along with a high incidence of venous thromboembolism in severe and critical COVID-19, have 12 led investigators to hypothesize that severe SARS-CoV-2 infection promotes a hypercoagulable 13 state, referred to as COVID-19-associated coagulopathy. 23-27 However, neither empiric 14 intermediate-dose prophylactic anticoagulation nor therapeutic anticoagulation for critical 15 COVID-19 appear to reduce thrombosis, the need for organ support, or mortality. [28] [29] [30] Emerging 16 bench studies and clinical observations suggest that thrombosis in COVID-19 may be primarily 17 immune-mediated and therefore targeting immunothrombosis may be essential to prevent or 18 treat thrombotic complications. 31,32 Clinical, patient-oriented studies have yet to test this 19 theory. 20 Whether cardiac microthrombi underlie acute cardiac injury in severe COVID-19 is 21 unclear at this time. Moreover, the mechanistic details of how SARS-CoV-2 triggers 22 immunothrombosis has not been determined. Prior COVID-19 cardiac autopsy series focused 1 primarily on detecting acute viral myocarditis and SARS-CoV-2. Most were limited to small 2 sample sizes (<50 persons) 11,13,14,16,17,33-35 and had long post-mortem intervals (PMI, i.e. the time 3 between death and autopsy). 13,33-36 Shown to compromise tissue RNA integrity and yield, 37 4 particularly that of the heart, 38 long PMIs hindered the potential molecular analyses of cardiac 5 tissue in prior COVID-19 autopsy studies. Moreover, the prevalence of cardiac microthrombi in 6 fatal COVID-19 is not well-established. 7 To investigate the molecular pathophysiology of cardiac injury and microthrombi in fatal 8 COVID-19, we instituted specific measures to reduce PMI and optimize autopsy specimen 9 quality for immunohistology and single nuclei RNA sequencing (snRNA-seq). We examined both 10 left and right ventricular cardiac tissue samples of COVID-19 decedents and determined the 11 prevalence of acute cardiac histopathologic features attributable to SARS-CoV-2 infection, 12 including cardiac microthrombi. We analyzed patient clinical data, ventricular viral load, and 13 histopathologic features of each heart to identify clinico-histopathologic associations that could 14 provide insight into the pathogenesis of COVID-19-associated cardiac injury and cardiac 15 microthrombi. We conducted snRNA-seq analysis of a subset of COVID-19 cardiac tissue with 16 and without microthrombi in order to determine the compositional and cell type-specific 17 transcriptomic changes that may underlie the development of COVID-19-associated cardiac 18 microthrombi. 19 Results 1 Patient Characteristics 2 Our study cohort of 69 laboratory-confirmed COVID-19 decedents had a mean age of 3 72±10 (range 38-97) years and 20 (29%) were women. Decedents were predominantly Hispanic 4 (59%) or Black (16%). Hypertension, diabetes, and obesity were the commonest comorbidities. 5 The median [IQR] time from hospitalization to death was 16 days. The majority of 6 patients had multiple organ failure with 59% supported on mechanical ventilation for 13 [2-34] 7 days, 54% receiving vasoactive medication, and 22% receiving renal replacement therapy. 8 Nearly 60% patients received corticosteroids; far fewer received tocilizumab (16%) or 9 remdesivir (3%). Peak high-sensitivity troponin (hs-TnT) exceeded 99 th percentile reference 10 limits in 93% of decedents; median peak hs-TnT was 99 [47-227] ng/L. D-dimer, ESR, and CRP 11 were also markedly elevated (Table 1 ). All autopsies were performed with a median PMI of 20 12 [5.5-42.5] hours; 20 autopsies had PMI <8 hrs. 13 Cardiac Histopathology 14 Upon immunohistologic examination of both left and right ventricular tissue samples of 15 the 69 hearts, we detected at least one of six acute cardiac histopathologic features in nearly all 16 decedents (n=67, 97%): microthrombi (n=48, 70%), microvascular endothelial cell damage 17 (n=25, 36%), scattered individual cardiomyocyte necrosis (n=25, 36%), focal cardiac necrosis 18 without any adjacent inflammatory infiltrate (n=14, 20%), focal inflammatory infiltrates without 19 associated cardiomyocyte injury (n=12, 17%), and focal myocarditis (n=4, 6%) (Fig. 1) . 20 Microthrombi were detected in serial sections by immunostaining for platelets (CD61). 21 Microvascular endothelial cell damage was identified by complement protein C4d 22 immunostaining, endothelial cell marker CD31 immunostaining, and by hematoxylin 1 counterstain. Necrotic cardiomyocytes were likewise identified by C4d immunostaining and 2 their characteristic branching, striated morphology appreciated on hematoxylin counterstain. 3 Focal cardiac necrosis was defined as a confluence adjacent C4d+ cardiomyocytes occupying an 4 area greater than 0.05mm 2 but not exceeding 1cm 2 . Inflammatory infiltrates were detected by 5 H&E staining. Most hearts (n=49, 71%) exhibited two or more of these acute histopathologic 6 features, including microthrombi in 39 (80%) of such cases (Fig. 1G ). Macroscopic and other 7 histopathologic autopsy findings are summarized in Supplemental Table ST1 . 8 In analyses adjusting for age and sex, microvascular endothelial damage was associated 9 with cardiac microthrombi in the corresponding ventricle (OR 3.58, 95% CI 1.46-8.80). 10 Cardiomyocyte necrosis, focal necrosis, inflammatory infiltrate, and myocarditis were not 11 independently associated with cardiac microthrombi (Supplemental Table ST2 ).

12 Ventricular Viral Load 13 We detected SARS-CoV-2 by RT-qPCR in 43 (62%) hearts. In analyses adjusting for age 14 and sex, detectable SARS-CoV-2 in ventricular tissue was independently associated with 15 microvascular endothelial cell damage in the corresponding ventricle (OR 2.36, 95% CI 1.04-16 5.35). In contrast, ventricular viral load was not associated with the presence of microthrombi 17 in the corresponding ventricle (Supplemental Table ST3 ). 18 Biomarkers and clinical risk factors 19 In generalized additive logistic models (GAMs) adjusted for demographic, clinical, and 20 COVID-19 treatment factors, peak hs-TnT and D-dimer were not associated with the predicted 21 risk of cardiac microthrombi but that peak CRP was linearly associated with the predicted risk of 22 cardiac microthrombi. ESR varied non-linearly with predicted risk of cardiac microthrombi, with 1 plateaus of risk at levels <60 and >100 mm/hr (Fig. 2) . In fully adjusted logistic regression 2 models, every 20 mg/L change in CRP was associated with a 1.17 (95% CI 1.00-1.36) higher odds 3 of cardiac microthrombi. Comparing patients in the third and fourth quartiles of ESR (107-126 4 and 130-169 mm/hr) to those in the first quartile (27-80 mm/hr), there was a 3.76 (95% CI 1.17-5 12.04) and 6.65 (95% CI 1.53-28.79) higher odds of cardiac microthrombi, respectively 6 (Supplemental Table ST4 ). 7 In models adjusted for demographic, clinical, and treatment factors, use of outpatient 8 antiplatelet therapy and in-hospital therapeutic anticoagulation were non-significantly 9 associated with a lower odds of cardiac microthrombi, whereas in-hospital corticosteroid 10 therapy was non-significantly associated with higher odds of cardiac microthrombi 11 (Supplemental Fig. S1 ). 12 Single Nuclei RNA Sequencing 13 To gain insight into the molecular pathophysiology of COVID-19-associated cardiac 14 microthrombi, we performed snRNA-seq on mid-right ventricular free wall tissue from eight 15 COVID-19 decedents with very low PMI (3.5 [2. .0] hrs)---four with and four without 16 microthrombi (Supplemental Table ST5 ). No SARS-CoV-2 transcripts were detected in any 17 sample---an expected reflection of the known non-nuclear, cytosolic residence of SARS-CoV-2. 18 We excluded one of the four microthrombi-positive samples from downstream analysis due to 19 its low cellular complexity and high mitochondrial read count (Supplemental Table ST6 ). We 20 compared data from the microthrombi-positive (13,068 cells) and microthrombi-negative 21 (30,425 cells) COVID-19 samples with each other and with data from six non-failing hearts of 22 the Human Cell Atlas (HCA) 39 as the non-COVID-19 reference cohort (32,279 cells). Generated 1 as part of a global effort to provide a non-failing reference map for analyses such as ours, the 2 HCA heart reference has the potential to yield technically-driven effects. To minimize such 3 potential, we reanalyzed the HCA reference from raw reads in parallel with our COVID-19 4 samples. Perfectly confounded, the HCA reference cohort could not be adjusted for any 5 differences in sample collection, sample processing, or library generation. Thus, results from 6 COVID-19 versus HCA reference comparison should be interpreted with this in mind. In 7 contrast, microthrombi-positive and microthrombi-negative COVID-19 samples were collected 8 and processed in parallel and therefore can be interpreted with greater confidence. 9 Principle components analysis of sample-level transcript counts clearly separated Table ST9 ). 6 We then identified the differentially expressed (DE) genes in the 9 most numerous cell 7 types across subset comparisons of: a) COVID-19 versus non-COVID-19 reference control and b) 8 microthrombi-positive versus microthrombi-negative COVID-19 (Supplemental Fig. S4 and Table   9 ST10). We examined gene set enrichment in all DE genes for each subset comparison (Fig. 3D , 10 Supplemental Table ST11 ). In COVID-19 versus reference control, multiple cell types shared 11 several altered regulatory patterns. Upregulation of chromatin modifying enzymes suggest 12 epigenetic changes in all but endothelial cells; and altered Rho-GTPases imply effects on 13 cytoskeletal dynamics and cell motility in non-immune cells. We also uncovered cell type-14 specific features in COVID-19 samples compared to reference controls. In vascular endothelial 15 cells, multiple pathways associated with IL-6 and interferon signaling were downregulated. By 16 examining the DE genes that comprised these pathways, we found significant and marked 17 downregulation of HLA class I proteins (HLA-A, B & C) and JAK/STAT family members----a 18 response that has been observed as a signature of viral immune evasion. 41 In cardiomyocytes 19 and vascular smooth muscle, pathways involved in striated and smooth muscle contraction 20 were respectively downregulated, driven by genes encoding structural components of contractile apparati (i.e., actinomyosin family members, troponins, and tropomyosins), 1 signifying contractile dysfunction. 2 Cell type-specific signaling signatures were also noted in microthrombi-positive 3 compared to microthrombi-negative COVID-19 specimens. In fibroblasts, extracellular matrix 4 (ECM) pathways were markedly upregulated, including multiple genes that encode collagen and 5 genes that encode proteins with dual anti-fibrinolytic/pro-thrombotic and innate immune 6 response-related functions, such as SERPINE1 and THBS2. In macrophages, cytokine signaling 7 was upregulated. In cardiomyocytes, striated muscle contraction pathways were further 8 downregulated, signifying more severe contractile dysfunction in microthrombi-positive COVID-9 19 hearts. 10 To assess cell-cell communication, we then examined the expression of receptor-ligand 11 pairs by each cell type population (Fig. 3E , Supplemental Table ST12 ). The number of cell-type 12 specific signaling interactions involving fibroblasts was notably greater in microthrombi-positive 13 compared to microthrombi-negative COVID-19 samples. With some autocrine and others 14 paracrine in nature, the additional fibroblast signaling interactions in microthrombi-positive 15 samples involved expression of multiple collagen types, the α11β1 integrin complex, and the 16 platelet-derived growth factor D (PDGFD) and PDGF receptor complex. 17 We then used a network representation learning framework 42 to identify regulator 18 genes--DE genes with the most connections to all other DE genes and to their gene ontologies. 19 We searched for regulator genes that account for both the differences between COVID-19 and 20 reference control (Supplemental Fig. S5 , Supplemental Table ST13 ) and those between 21 microthrombi-positive and microthrombi-negative COVID-19 samples (Fig. 3F ). In sum, we 22 identified 254 unique regulator genes, distributed across all cell types, that accounted for the 1 differences between microthrombi-positive and microthrombi-negative COVID-19 samples 2 (Supplemental Table ST13 ). Nearly a third of these regulator genes were shared by multiple cell 3 types, indicating that a common cellular response is specific to COVID-19-associated cardiac 4 microthrombi at the tissue level. To identify regulator genes with larger effect sizes, we 5 examined genes with greater differential expression (>0.5 LFC) between the microthrombi-6 positive and microthrombi-negative COVID-19 subsets. We uncovered 17 such large-effect 7 regulator genes in fibroblasts and 9 in pericytes but none in any other cell types (Fig. 3F , 8 Supplemental Tables ST13). Notably, FGFR1 was one of the fibroblast-specific large-effect Given the convergence of pro-fibrotic fibroblast signatures, we wished to specifically 1 examine the activation state of fibroblasts in microthrombi-positive COVID-19 samples. We 2 examined the expression of canonical markers of fibroblast activation, FAP and POSTN, in our 3 snRNA-seq data. While we observed that the percentage of fibroblasts expressing these 4 markers and the mean expression of these markers were higher in microthrombi-positive 5 versus microthrombi-negative COVID-19 samples, they were not expressed broadly enough to 6 be included in our wider DE model (Fig. 4A,B) . To examine this further, we performed RT-qPCR Discussion 1 We conducted the first combined clinico-histopathologic and single cell analysis of a 2 prospective COVID-19 cardiac autopsy cohort. We identified microthrombi as the predominant 3 acute cardiac histopathologic feature in fatal COVID-19 and applied a multidisciplinary 4 approach to investigating the pathophysiology of COVID-19-associated cardiac microthrombi. 5 We found that biomarkers of systemic inflammation, but not those of fibrinolysis or cardiac 6 injury, are independently associated with cardiac microthrombi, supporting an 7 immunothrombotic mechanism of microthrombi formation. Our findings that anti-platelet and 8 anticoagulation therapy have a non-significant association with a lower odds of cardiac 9 microthrombi suggest that anticoagulation may be necessary but is insufficient in preventing 10 and treating cardiac microthrombi in COVID-19. Our snRNA-seq analysis suggests that 11 dysregulated cardiac fibroblasts expressing high levels of pro-thrombotic/anti-fibrinolytic, ECM-12 remodeling, and immune-potentiating genes are a salient feature of COVID-19-associated 13 cardiac microthrombi. Thus, our cumulative findings provide new insights into the processes 14 that may underlie COVID-19-associated immunothrombosis and cardiac microthrombi, with 15 potential therapeutic implications for targeting cardiac fibroblast activity. 16 Our study is distinct from prior sc/snRNA-seq analyses of COVID-19 tissue with and without microthrombi provided an internal control for changes associated more 1 generally with severe COVID-19. It enabled us to identify the cellular and transcriptomic 2 changes that are most likely to be specific to cardiac microthrombi in severe COVID-19. Second, 3 we examined associations of serum biomarkers with cardiac microthrombi, while controlling for 4 multiple clinical covariates, including in-hospital therapies. Our findings suggest that an 5 inflammatory process underlies cardiac microthrombi in COVID-19. Third, we also found an 6 association, independent of age and sex, between cardiac microvascular endothelial cell 7 damage and cardiac microthrombi in our cohort of COVID-19 decedents. This association is 8 consistent with the understanding that immunothrombosis occurs in the context of endothelial 9 cell dysfunction, immune cell activation, and platelet activation. 46 That microthrombi in COVID-10 19 is an immunothrombotic phenomenon has been widely assumed but, to date, unproven.

The synergy of our clinical, histopathological, and molecular findings bolsters our conclusion 12 that cardiac microthrombi in critical COVID-19 is indeed an immunothrombotic event, and not 13 the result of disordered fibrinolysis and coagulation alone. 14 Additional strengths of our study include our cohort demographics and low PMI. Our proportion of cardiomyocytes in COVID-19 relative to reference control samples, along with the 10 low prevalence of focal cardiac necrosis and the lack of association between cardiac 11 microthrombi and cardiac necrosis in our overall COVID-19 cohort, suggests that the loss of 12 cardiomyocytes is due to non-necrotic cell death. Additional non-necrotic causes of serum cTn 13 elevation, such as increased cardiomyocyte membrane permeability and vesicular release from 14 cardiomyocytes, 52,53 may also be involved but are beyond the scope of our current study. We 15 found no association between ventricular SARS-CoV-2 viral load and peak serum hs-cTn-T, 16 suggesting that acute cardiac injury is likely an indirect effect of COVID-19. Moreover, no 17 evidence of SARS-CoV-2 infection of cardiomyocytes emerged from our snRNA-seq analysis, 18 further pointing towards an indirect mechanism of cardiomyocyte injury. Our snRNA-seq data 19 also puts forth the possibility that cardiomyocyte injury in COVID-19 may be attributable to 20 upregulation of cytokine signaling by macrophages within the heart. Upregulated macrophage 21 cytokine signaling may also lead to cardiac pericyte cell death in COVID-19, as a lower 22 proportion of pericytes, without any transcriptomic evidence of SARS-CoV-2 infection, was also 1 observed in COVID-19 samples versus reference controls. Further studies are needed to 2 determine the details of such an indirect mechanism of cardiomyocyte and pericyte cell death 3 in severe COVID-19. 4 Our foremost discovery, on snRNA-seq analysis, is the specific prothrombotic, anti-5 fibrinolytic, and immune activating signaling of cardiac fibroblasts in microthrombi-positive 6 COVID-19 hearts. We identified pro-fibrotic responses in COVID-19 samples which can promote 7 in situ microthrombi formation, particularly ECM deposition pathways that include secreted 8 proteins with dual pro-thrombotic/anti-fibrinolytic and innate immune response functions. Patients were hospitalized prior to FDA-approved therapies, and our initial local 6 practice, as of April 15, 2020, was to reserve steroids for only the most critically-ill appearing 7 patients. Therefore, the nearly statistically significant association of steroid use with increased 8 odds of cardiac microthrombi may reflect some confounding by an unmeasured greater 9 severity of illness. During the study period, testing for other respiratory viruses (i.e., influenza 10 or adenovirus) was not routine. Reassuringly, a study of suspected acute myocarditis patients 11 earlier in the pandemic offers evidence that viral co-infection occurs <5% of the time. 54 Our 12 observed associations between clinical variables and presence of cardiac microthrombi may be 13 affected by unmeasured residual confounding and missingness, though we were able to adjust 14 for several confounders via CBPS and we employed multiple imputation. The magnitude of the 15 effect estimates may not be generalizable given our single-center study design. 16 While affording previously unattainable resolution of cell type-specific transcription, 17 snRNA-seq analyses have technological limitations which are discussed extensively in the 18 results and on-line methods as they arise. Importantly, SARS-CoV-2 resides in the cytosol, which 19 is removed during sample processing for snRNA-seq. As such, we could not and did not observe 1 We are indebted to the families who provided next-of-kin consent for autopsy of their loved 2 one. We also wish to thank the NYP-CUIMC clinicians who cared for COVID-19 patients and the Quality control was performed on the individual sample level. For each cell, we 12 calculated the ratio of reads mapping to exonic regions to total mapped reads using Scrinvex 13 (version 13) (https://github.com/getzlab/scrinvex). Cells with an exon ratio greater than the 14 75 th percentile + IQR range were removed from downstream analyses due to increased 15 cytoplasmic transcripts (3,182 cells). We also excluded droplets which contained more than one 16 nucleus as identified by Scrublet 63 (10,866 cells). Samples were also filtered to remove cells 17 with reads mapped to less than 200 genes (11,280 cells) and cells with greater than 5% 18 mitochondrial reads (9,825 cells). 19 The gene list was filtered for highly variable genes (minimum mean 0.0125, maximum 20 mean 3, minimum dispersion 0.5), using a subset of 6,255 genes for cell clustering. To account for variable complexity per nucleus, counts were normalized to 10,000 unique molecules per 1 nucleus and logarithmized. Total read count and % mitochondrial reads were regressed out 2 (Scanpy preprocessing regress_out); data was scaled to a maximum value of 10. Ischemic time 3 for non-COVID-19 reference controlsError! Hyperlink reference not valid. was unavailable. Hence, 4 we could not account for effects of ischemic time; results relating to hypoxic signaling should be 5 interpreted with caution. 6 We calculated principal components from the highly variable gene subset 7 (scanpy.tl.pca(adata, svd_solver='arpack')) and then corrected the normalized data for batch 8 effects using Harmonypy (version 0.0.5) 64 with each sample considered as a unique batch. We 9 used the batch-corrected PCs to calculate neighbors (scanpy.pp.neighbors(adata, 10 n_neighbors=10, n_pcs=40)) and generate a UMAP (scanpy.tl.umap(adata)). Cells were then 11 clustered using leiden clustering (scanpy.tl.leiden(adata)) at a resolution of 0.225. 12 Marker gene and cell type identification 13 Genes were ranked using a Wilcoxon rank sum test (scanpy rank_genes_groups) for 14 each cell-type cluster versus all other cells; and log2-fold change (FC) and percentage of cells 15 expressing each gene were calculated. Area under the receiver operator curve (AUC) scores 16 were calculated for all genes within each cell cluster using SciKit Learn roc_auc_score. Genes 17 were considered markers of a given cluster with an AUC score >0.7 or a log2-FC >0.6. 18 Compositional analyses 19 The proportion of each cell type was compared across samples using scCODA (version Credible interval differences in cell type proportions were determined using spike-and-slab 3 inclusion probabilities. Importantly, the proportion of a given cell type in a sample is governed 4 by our ability to liberate the nuclei equivalently from the tissue and our ability to successfully 5 identify cells compared to empty droplets. The former may be affected by cell death or 6 increased fibrosis which our sectioning protocol is designed to mitigate. The latter is a more 7 challenging problem for single nucleus RNA sequencing, which is influenced by the relative 8 transcriptional complexity of various cell types, making transcript rich cell types such as 9 cardiomyocytes and fibroblasts easy to identify with transcript poor cells such as immune cells 10 more apt to be assigned as an empty droplet. Use of a probabilistic cell calling mechanism in 11 CellBender 62 is used to overcome this challenge. included. DEGs were identified based on an Benjamini-Hochberg false discovery rate (FDR) 20 adjusted P-value <0.05. Importantly, each droplet is contaminated by ambient RNA, which is 21 imperfectly removed informatically by design. Therefore, DE results should be interpreted with 22 caution, particularly when examining non-major cell types (e.g., intracardiac neurons, lymphatic 1 endothelial, mast cells) and genes highly expressed in cells as numerous as cardiomyocytes. 2 Genes which serve as markers of another cluster (AUC > 0.7) were blacklisted to exclude 3 potential differential contamination by ambient RNA as a driver of such effect. Gene lists were 4 also compared to the secreted protein list obtained from the Human Protein Atlas 5 (proteinatlas.org). Full lists of DE genes, including those which were blacklisted, are contained 6 in Supplemental Table ST3 . Supplemental Table ST11. 14 Cell-Cell Communication iterations for generation of null distribution, curated interactions list compiled by CellphoneDB 1 from UniProt, Ensembl, PDB, IMEx consortium, and IUPHAR). 2 Regulator Genes 3 To identify regulator genes that function within and likely drive gene networks within a 4 biological context, we analyzed DEGs with a log2-FC >0.5 for each cell type using GeneWalk 42 5 (direction of differential expression was not incorporated). GeneWalk builds biologically 6 relevant networks from provided gene lists, connecting genes and GO terms, and compares the 7 network to random networks. GeneWalk was used with default parameters and an FDR-8 corrected P-value of 0.1. The identified regulator genes were compared to a list of druggable 9 genes. 43 The full list of regulator genes identified is available in Supplemental Table ST13. 10 Statistical Analysis 11 We tested associations between the presence of ventricular SARS-CoV-2 and 12 histopathologic findings using logistic regression while adjusting for age and sex. We examined 13 unadjusted associations of demographic, clinical, and laboratory characteristics with the 14 presence of cardiac microthrombi in COVID-19 hearts using Student's t, Mann-Whitney, or χ 2 15 tests. For laboratory markers with greater than 5% missingness, we used multiple imputation in 16 unadjusted tests of association. We created separate generalized additive logistic models interval in days between death and documented onset of symptoms consistent with COVID-19 1 or initial contact with health care system for symptoms consistent with COVID-19), outpatient 2 ACEi/ARB use, outpatient antiplatelet therapy, and inpatient administration of corticosteroids, 3 remdesivir, interleukin-6 (IL-6) receptor antagonists, and therapeutic anticoagulation. We 4 estimated adjusted odds ratios using logistic regression models if there was no evidence of non-5 linearity in the GAMs. Since ESR had a non-linear association, we estimated odds ratios for each 6 quartile increase in biomarker concentration. We also examined associations of treatments 7 with cardiac microthrombi using logistic regression with CBPS to adjust for age, sex, race-8 ethnicity, BMI, and duration of COVID-19 illness, remdesivir, and IL-6 receptor antagonists. Detection of SARS-CoV-2 in cardiac tissue, decedents' age and sex are also shown. 

Cardiac Arrhythmias in COVID-19 Infection

Multisystem Inflammatory Syndrome After COVID-19

ST-Segment Elevation in Patients with Covid-19 -A Case Series

A Recovered Case of COVID-19 Myocarditis and ARDS Treated with 10

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient 14 with SARS-CoV-2 respiratory infection

Clinical and hemodynamic effects of intra-aortic balloon pump therapy in 16 chronic heart failure patients with cardiogenic shock

The Variety of Cardiovascular Presentations of COVID-19

Prevalence and Impact of Myocardial Injury in Patients Hospitalized With 21 COVID-19 Infection

Cumulus provides cloud-based data analysis for large-scale single-cell and single-6 nucleus RNA-seq

Cutadapt removes adapter sequences from high-throughput sequencing reads

CellBender remove-background: a deep generative 10 model for unsupervised removal of background noise from scRNA-seq datasets. bioRxiv

Computational Identification of Cell Doublets 13 in Single-Cell Transcriptomic Data

Fast, sensitive and accurate integration of single-cell data with Harmony

A Bayesian model for 17 compositional single-cell data analysis. bioRxiv

MAST: a flexible statistical framework for assessing transcriptional changes 19 and characterizing heterogeneity in single-cell RNA sequencing data

The reactome pathway knowledgebase